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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYThe differentiation of pluripotent stem cells to hepatocytes is well established, yet current methods suffer from several drawbacks. These
include a lack of definition and reproducibility, which in part stems from continued reliance on recombinant growth factors. This has
remained a stumbling block for the translation of the technology into industry and the clinic for reasons associatedwith cost and quality.
We have devised a growth-factor-free protocol that relies on small molecules to differentiate human pluripotent stem cells toward a
hepatic phenotype. The procedure can efficiently direct both human embryonic stem cells and induced pluripotent stem cells to hepa-
tocyte-like cells. The final population of cells demonstrates marker expression at the transcriptional and protein levels, as well as key
hepatic functions such as serum protein production, glycogen storage, and cytochrome P450 activity.INTRODUCTION
Human embryonic stem cells (hESCs) and induced plurip-
otent stem cells (hiPSCs) offer a potentially limitless source
of cells for industrial and clinical translation, and the ever-
advancing field of cellular reprogramming has redefined
the limits of cell plasticity (Taylor et al., 2010). Meanwhile,
cell culture and production technologies are rapidly
improving, and the first instances of pluripotent-cell-
derived therapies have entered clinical trials (Schwartz
et al., 2012).
Amidst this broadening field, hepatocyte generation is
gathering interest with industrial and clinical parties due
to its relevance in the areas of drug development, cell
therapy, and disease modeling. While the scope of what
could be achieved is wide, a number of obstacles remain
before human pluripotent stem cell (hPSC) technologies
can be adopted for widespread use. On the one hand are
the technical challenges relating to scalability, definition,
and reproducibility, while from a basic research perspec-
tive, many unanswered questions remain regarding the
development of an adult phenotype, the mechanisms of
cell reprogramming, and the role of the tissue culture
microenvironment.
Early protocols for the generation of hepatocytes from
pluripotent cells relied on the use of embryoid body for-
mation (Baharvand et al., 2006; Basma et al., 2009; Ima-
mura et al., 2004). This method involves the creation of
cell aggregates and the spontaneous differentiation of
the pluripotent population to a mixed population of cells
representing the three germ layers (Itskovitz-Eldor et al.,
2000). Notable improvements in efficiency and function-Stemality have since been achieved by various groups, which
based their protocols on developmental signaling and uti-
lized adherent culture conditions. However, all directed
differentiation protocols for hepatocyte-like cells (HLCs)
published to date have relied on the use of recombi-
nant growth factors such as activin A, Wnt3a, hepatocyte
growth factor (HGF), oncostatin M (OSM), fibroblast
growth factor 4 (FGF4), vascular endothelial growth factor
(VEGF), epidermal growth factor (EGF), and bone
morphogenetic protein 4 (BMP4) (Agarwal et al., 2008;
Brole´n et al., 2010; Cai et al., 2007; Chen et al., 2012;
Hay et al., 2008; Liu et al., 2010; Si-Tayeb et al., 2010b;
Song et al., 2009; Sullivan et al., 2010; Touboul et al.,
2010).
Some recent progress has been made in replacing
growth factors for the differentiation of mesoderm and
ectoderm (Chambers et al., 2012; Lian et al., 2012), and
efforts have been undertaken to find suitable candidates
for the production of definitive endoderm (DE), exempli-
fied by the Melton group, who identified IDE1 and 2
(Borowiak et al., 2009). Recent studies have also demon-
strated the utility of other small molecules in priming
pluripotent cells for differentiation toward endoderm
(Tahamtani et al., 2013) and mesoderm (Tan et al.,
2013). To date, however, further endodermal differentia-
tion has only been performed in combination with other
recombinant growth factors (for a review, see Han et al.,
2012).
A number of publications have demonstrated that
Wnt signaling is required to specify DE (Engert et al.,
2013; Nakanishi et al., 2009), and we have found that
a pulse of GSK-3 inhibition is sufficient to produceCell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authors 939
Figure 1. Schematic of the Differentiation Process
(A) The normal process of differentiation and the phases of the protocol to which these apply.
(B) Summary of the base media, time course, and small-molecule additions for each phase of differentiation.
(C) Key markers expressed at each stage of differentiation.
(D) Representative morphology of H1 cells observed at key stages of differentiation using phase contrast microscopy (103). Scale
bars, 100 mm.
See also Figure S1.populations of DE at a high efficiency. We are then able
to direct the small-molecule-generated population of DE
to functional HLCs with a combination of small mole-
cules, namely DMSO, dexamethasone (DEX), and an
HGF receptor agonist N-hexanoic-Tyr, Ile-(6) aminohexa-
noic amide (dihexa) (McCoy et al., 2013). This stepwise
approach is able to generate HLCs at high efficiency,
without the inclusion of growth factors (Figure 1). The
differentiated cells demonstrate similar levels of func-
tion to those derived via published growth-factor-based
approaches.940 Stem Cell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The AuthoRESULTS
Production of DE Using GSK-3 Inhibition: Phase I
The ability to produce hepatocytes from hPSCs that have
utility in both clinical and research arenas will require
methodologies that are robust in terms of efficiency and
reproducibility. The majority of methodologies to date are
far from this and also reliant on recombinant growth fac-
tors to direct cellular fate. This will prove a major hurdle
if these cells are to be utilized in a therapeutic environ-
ment. We have therefore developed a differentiationrs
procedure that is devoid of growth factors and driven by
small molecules. The procedure is notionally trisected
into three phases inducing DE differentiation (phase I), he-
patic specification (phase II), and hepatocyte maturation
(phase III).
Following studies of the utility of GSK-3 inhibition in
priming pluripotent cells for endodermal differentiation
(Tahamtani et al., 2013) and reports that Wnt/b-catenin
signaling regulates SOX17 expression and is essential for
endoderm formation (Engert et al., 2013), we set out to
establish whether we could use this approach as a starting
point for the generation of functional hepatocytes. We
initially established the conditions for DE differentiation
in the hESC line H1. Through a 24-hr treatment with
3 mMCHIR99021, followed by 24 hr of non-directed differ-
entiation in RPMI-B27, we were able to guide hPSCs
through developmentally relevant stages to produce a pop-
ulation of DE (Figure 2A). Over a 48-hr period, we observed
dynamic changes in the gene expression pattern (Figure 3).
By 48 hr, we observed elevated expression of DE markers
such as FOXA2, GSC, SOX17, HHEX, and CER1 (Ang
et al., 1993; Blum et al., 1992; Kanai-Azuma et al., 2002;
Monaghan et al., 1993; Sasaki and Hogan, 1993). In addi-
tion, early events of the differentiation indicated transition
through a primitive streak (PS) intermediate.We observed a
rapid upregulation of NODAL within 4 hr of exposure to
CHIR99021, which is indicative of a transition toward a
PS population (Figure 3) (Lu et al., 2001). This was followed
by induction of the PS markers T and GSC (Figure 3). The
markers SOX17, GSC, FOXA2, and MIXL1 are expressed in
extra-embryonic endodermal lineages as well as DE. In
order to demonstrate that our differentiation procedure
was not producing primitive endoderm, we examined the
levels of SOX7 and observed no upregulation during our
procedure (Figure 2A). The observed patterns of expression
are similar to those seen with a 3-day treatment of activin A
and Wnt3a or a 5-day treatment of activin A (D’Amour
et al., 2005; Hay et al., 2008). These changes in gene
expression were accompanied by morphological changes;
the cells shifted from a pluripotent morphology to
dense, bright clusters at 24 hr, followed by a petal-like
morphology at 48 hr (Figure 2B). At the 48-hr time point
(phase I endpoint), we observed co-expression of FOXA2
and SOX17 at the protein level using immunofluorescence
(Figure 2C). We then compared treatments with activin
A/Wnt3a, CHIR99021, and vehicle control and found
equivalent co-expression of the DE proteins FOXA2 and
SOX17 by immunofluorescence in the growth-factor- and
small-molecule-treated cells (Figure 2C) and no co-expres-
sion in the control (data not shown). Next, we assessed
whether GSK-3 inhibition was a generic mechanism to
drive hPSCs to DE. Figure 2C demonstrates the utility of
an alternative GSK-3 inhibitor (BIO, 1 mM) to produceStemFOXA2/SOX17-positive cells under the same conditions,
suggesting that GSK-3 inhibition followed by its removal
is responsible for commitment toDE. It is well documented
that BIO and CHIR99021 are potent pharmacological GSK-
3-specific inhibitors that result in activation of the Wnt
signaling pathway (Sato et al., 2004; Sineva and Pospelov,
2010), so we next assessed the ability of the protein
Wnt3a alone to drive differentiation toward DE. Figure 2C
demonstrates that treatment with Wnt3a was sufficient to
produce populations of cells that expressed the DEmarkers
FOXA2 and SOX17. This observation indicates that Wnt3a
treatment alone can facilitate the production of DE and
that the inclusion of activin A is not necessary for DE pro-
duction in vitro. All treatments described gave similar effi-
ciencies with respect to FOXA2- and SOX17-positive cells:
78%–85% for FOXA2 and 79%–87% for SOX17 (Figure 2D).
Hepatic Specification through DMSO Treatment of
Definitive Endoderm: Phase II
Following the production of DE through small-molecule
stimulation, the next step was to specify a hepatic fate.
We explored potential routes to efficiently produce an
AFP/HNF4A-positive hepatic progenitor population. There
are numerous reports of the utility of the small molecule
DMSO in stem cell differentiation and specifically in the
generation of hepatic progenitors (Hay et al., 2008; Ramb-
hatla et al., 2003; Soto-Gutierrez et al., 2006; Sullivan et al.,
2010). Therefore, we used a well-established method con-
sisting of a 5-day treatment with 1% DMSO. On subjecting
DE to phase II conditions (DMSO), we observed a rapid
change in morphology and a spurt of proliferation. After
the 5 days of treatment, we observed 87% co-expression
of AFP and HNF4A, as assessed by immunofluorescence
(Figures 4A and 4B). This was comparable to activin
A/Wnt3a followed by DMSO treatment, in line with previ-
ous reports (Figures 4A and 4B). In addition, the cells
exhibited typical hepatocyte progenitor morphology as
assessed by phase contrast microscopy (Figure 4C). The
levels of AFP/HNF4A co-expression observed are indicative
that this phase of the differentiation is extremely efficient
(Figure 4B). Gene expression was analyzed after the end
of hepatic specification by qRT-PCR (Figure 4D), and the
panel shows a repertoire of hepatic progenitor markers
that were expressed including AFP, CEBPA, FOXA2,
GATA4, HNF4A, PROX1, TBX3, and TTR. To assess the dif-
ferentiation of DE to hepatic progenitors (hepatoblasts),
we monitored the gene expression levels of several key
developmental markers, which are known to regulate hep-
atoblast formation in vivo, during the 5-day phase II
protocol (Si-Tayeb et al., 2010a). We observed that both
small-molecule- and growth-factor-derived DE (hESC
line H1) followed a similar trajectory toward hepatic
progenitors (Figure 5). During differentiation to hepaticCell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authors 941
Figure 2. Characterization of Phase I Differentiation: Definitive Endoderm
(A) Gene expression changes during phase I of differentiation as measured by TaqMan qRT-PCR. Blue progression, small-molecule
treatment after 24 and 48 hr. Green progression, vehicle control at 24 and 48 hr. Yellow-red progression, published growth-factor-based
method (Hay et al., 2008) at 24, 48, and 72 hr. All were performed using H1 hESCs and normalized to ACTB and undifferentiated control.
Data are presented as the mean of three independent experiments; error bars represent SD.
(B) Comparison of morphology of growth factor and small-molecule definitive endoderm differentiation at days 0, 1, and 3 for growth
factor and days 0, 1, and 2 for small molecule, taken using phase contrast microscopy (103). Scale bars, 100 mm.
(C) Expression of FOXA2 and SOX17 at phase I endpoint after treatment with activin/Wnt3a, CHIR99021, BIO, or Wnt3a alone, imaged
using fluorescent microscopy. The treatment is indicated at the head of each column. Scale bars, 100 mm.
(D) Efficiency of phase I differentiation, determined by counting FOXA2-positive cells and SOX17-positive cells. Efficiencies are presented
as the percentage of positive cells plus or minus the SD of all fields counted.
See also Figure S2.progenitors, we observed maintenance of FOXA2 levels
and an induction of GATA4, both of which are known to
be pioneer factors critical to promote the hepatic gene
expression program (Kaestner, 2005). Over the 5 days,942 Stem Cell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authothere was an increase in expression of PROX1 and TBX3,
which are believed to interact in vivo to promote themigra-
tion and proliferation of hepatoblasts from the primary
liver bud (Sosa-Pineda et al., 2000; Lu¨dtke et al., 2009).rs
Figure 3. Phase I 48-Hr Time Course
to Assess Developmental Trajectory by
qRT-PCR
The human embryonic stem cell line H1 was
differentiated in RPMI-B27 supplemented
with 3 mM CHIR99021. The expression pro-
files of key genes were examined to estab-
lish the dynamics of the differentiation
process. We monitored developmentally
relevant markers of primitive streak
(T, MIXL1, GSC, and FOXA2), mesendoderm
(T and FOXA2), and definitive endoderm
(HHEX, CER1, SOX17, and FOXA2). Cells were
collected for analysis every 4 hr for 48 hr
(phase I: DE stage). Data are presented as
the mean of three independent experi-
ments; error bars represent SD. The x axis
represents the time (in hours) after the
start of differentiation. The y axis repre-
sents the log10 relative quantification (RQ)
values from the TaqMan analysis. See also
Figure S3.Furthermore, we analyzed several key regulators and
markers of hepatocyte differentiation and observed strong
induction of CEBPA, HNF4A, TTR, and AFP.
Production of HLCs via Dexamethasone and the HGF
Receptor Agonist Dihexa: Phase III
The final stage of HLC differentiation (hepatic maturation)
has been performed by many groups using a wide range of
growth factors such as HGF, OSM, FGF4, VEGF, and EGF
(Han et al., 2012). We assessed the literature landscape to
find potential small-molecule mimetics of growth factorsSteminvolved in hepatocytematuration and identified a potent,
stable HGF receptor agonist, N-hexanoic-Tyr, Ile-(6) amino-
hexanoic amide (dihexa). This molecule was originally
developed as a potential therapeutic intervention for
neurodegenerative disorders such as Alzheimer’s disease
(McCoy et al., 2013). In addition, we utilized the small-
molecule glucocorticoid mimetic dexamethasone (DEX),
which is well established in hepatocyte maturation
procedures.
We tested a number of base media to establish the
optimal concentrations of DEX and dihexa. We initiallyCell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authors 943
Figure 4. Characterization of Phase II
Differentiation: Hepatic Specification
(A) Expression of AFP and HNF4A at phase II
endpoint of growth-factor- and small-
molecule-treated cells, imaged using fluo-
rescent microscopy. Treatment is indicated
at the head of each column. Scale bars,
100 mm.
(B) Efficiency of phase II differentiation,
determined by counting AFP and HNF4A
double-positive cells. Efficiencies are pre-
sented as the percentage of positive cells
plus or minus the SD of all fields counted.
(C) Morphology at phase II endpoint, pho-
tographed using phase contrast microscopy
at 103 and 203. Scale bars, 100 mm.
(D) Expression of AFP CEBPA, FOXA2,
GATA4, HHEX, HNF4A, PROX1, SOX17, TBX3,
and TTR at phase II endpoint following
either growth-factor (red) or small-mole-
cule (blue) treatments, as measured by
TaqMan. Normalized to ACTB and growth-
factor- or small-molecule-derived definitive
endoderm, respectively. Data are presented
as the mean of three independent experi-
ments; error bars represent SD.
See also Figure S4.used the proprietary media HepatoZYME (Life Technolo-
gies) and established the optimal concentrations of DEX
and dihexa as being 100 nM for each (data not shown).
However, HepatoZYME is a proprietary reagent and con-
tains the growth factor EGF and thus was unsuitable for
this application (Garcia et al., 2001). We next assessed Wil-
liam’s basemedium, as this is used in a number of protocols
for hepatocyte differentiation. Both DEX and dihexa were
required, and the above concentrations gave the best re-
sults in terms of morphology and function, but this media
was not optimal in our hands (data not shown). We finally
settled on a modified formulation of Leibovitz L-15 me-
dium (L-15), which has been described in the literature as
a standard method to generate mature hepatocytes (Hay
et al., 2008; Sullivan et al., 2010). L-15mediumwas supple-
mented with DEX and dihexa (both at 100 nM), which led
to the production of cells displaying typical hepatocyte
morphology at the endpoint of the small-molecule-driven
differentiation protocol (Figure 6A). The cells were large
and angular with bright junctions and in some instances
contained multiple nuclei. The resulting HLCs demon-
strated expression of the hepatocyte markers albumin
(ALB), HNF4A, alpha-1-antitrypsin (A1AT), and AFP by
immunofluorescence (Figures 6B–6D). Comparable data
can be seen for growth-factor-based differentiation in Fig-
ures 6B–6D. We observed comparable efficiencies of differ-
entiation between the growth-factor and small-molecule944 Stem Cell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authoapproaches by assessing ALB/HNF4A, A1AT, and AFP (Fig-
ure 6E). To corroborate that the source of the HLCs is
from DE rather than from yolk sac, we demonstrated that
the DE origin marker CYP7A1 was expressed (Asahina
et al., 2004) (Figure 6F). To ensure that the protocol was
equivalent to previously described growth-factor-based
methods, we produced functional hepatocytes as described
byHay and colleagues (Hay et al., 2008) (see Figures 6B–6D)
for validation. Gene expression was analyzed by qRT-PCR
(Figure 7A), and the panel shows a repertoire of hepatic
markers that were expressed: A1AT (SERPINA1), AFP, ALB,
APOA2, ASGR1, CYP3A4, HNF4A, TDO2, and TTR. The
observed relative levels of expression were very similar irre-
spective of being derived via the growth-factor- or small-
molecule-based protocol (Figure 7A). We observed similar
level of expression with respect to fetal hepatocytes for
A1AT (SERPINA1), APOA2, ASGR1, HNF4A, and TTR. How-
ever, we observed higher levels of expression of AFP for
both small-molecule- and growth-factor-derived HLCs
compared to adult and fetal hepatocytes. In all cases,
except for AFP, we observed higher levels of expression of
all hepatic markers in primary adult hepatocytes.
Small-Molecule-Derived HLCs Demonstrate Hepatic
Function
Above, we have shown that small-molecule-derived HLCs
(smHLCs) exhibit hepatic morphology and expression ofrs
Figure 5. Phase II 5-Day Time Course
The human embryonic stem cell line H1 was
differentiated to definitive endoderm using
either the small-molecule (blue) or growth-
factor (red) protocol. Definitive endoderm
was treated with 1% DMSO to differentiate
to hepatic progenitors, and cells were
collected every 24 hr for 5 days to assess the
gene expression of developmentally rele-
vant hepatic markers. Data are presented as
the mean of three independent experi-
ments; error bars represent SD. The x axis
represents the time (in days) after defini-
tive endoderm. The y axis represents the RQ
values from the TaqMan analysis. See also
Figure S5.hepatocyte-specific markers at the transcriptional and pro-
tein levels. We next assessed whether smHLCs displayed
functional hepatic characteristics. An important function
of hepatocytes is the ability to clear xenobiotics via
metabolism through the cytochrome P450 isoenzymes.
We assessed smHLCs for their metabolic potential, as
compared to growth-factor-derived HLCs. The cytochrome
P450 enzymes (CYP) are critical in drug metabolism, in
particular CYP1A2 and CYP3A4. We assessed the function
of these CYPs in terms of their basal activity and their abil-Stemity to be induced by rifampicin (CYP3A4) and omeprazole
(CYP1A2). We observed higher basal CYP activity in the
smHLCs as compared to hESC H1 controls for both
CYP1A2 and 3A4 (Figure 7B). On challenge with known in-
ducers of these enzymes, we observed significant induction
of both CYPs, to a similar degree as in growth-factor-
derived HLCs (Figure 7B). Another key function of hepato-
cytes is the production of serum proteins, so we examined
the ability of the smHLCs to secrete albumin, alpha-1-anti-
trypsin, and fibronectin by ELISA. All three proteins wereCell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authors 945
Figure 6. Characterization of Phase III Differentiation to Hepatocyte-like Cells: Morphology and Immunofluorescence
(A) Morphology of growth-factor and small-molecule protocol endpoints, taken using phase contrast microscopy at 103. Scale bars,
100 mm.
(B) Expression of albumin and HNF4A at protocol endpoints, imaged using fluorescent microscopy. Treatment is indicated at the head of
each column. Scale bars, 100 mm.
(C) Expression of A1AT at protocol endpoints, imaged using fluorescent microscopy. Treatment is indicated at the head of each column.
Scale bars, 100 mm.
(D) Expression of AFP at protocol endpoint was imaged using fluorescent microscopy. Treatment is indicated at the head of each column.
Scale bars, 100 mm.
(legend continued on next page)
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detected in the medium at levels similar to those seen
from growth-factor-derived cells (Figure 7C). Another
function tested was the ability to store glycogen. smHLCs
were stained with periodic acid Schiff (PAS) and counter-
stained with H&E. We observed extensive cytoplasmic
staining (pink to purple), indicative of glycogen storage,
at levels similar to those observed in growth-factor-
derived hepatocytes (Figure 7D). We also examined the
uptake of indocyanine green (ICG) in smHLCs; after a
brief treatment, ICG-positive cells were clearly visible
(Figure 7E).
smHLCs Can Be Derived from Multiple Human
Pluripotent Stem Cell Lines
An important attribute of any differentiationmethodology
is the ability to translate it to other cell lines. This is espe-
cially important in the case of hiPSCs, as these will provide
a basis to model hepatic disease and potentially lead to the
development of personalized medicine. In addition, the
ability to derive hepatocytes of a defined genotype will be
of utility in the areas of toxicology and drug development.
To test this, we assessed the potential of a number of hPSC
lines. We tested one additional hESC line (207) and three
different hiPSC clones derived from the fibroblast line
Detroit 551 (RA, RB, and RC), using the conditions applied
to the hESC line H1.
Through an initial 24-hr treatment with 3 mM
CHIR99021, followed by 24 hr of non-directed differentia-
tion in RPMI-B27, we observed that the differentiation was
very inefficient and did not produce the predicted
morphology (data not shown) as previously observed for
the hESC line H1 (Figure 2B). We next performed a titra-
tion of the small molecule CHIR99021 (1–10 mM) in
RPMI-B27 ± insulin (Figure S1C). The optimal concentra-
tion for CHIR99021 was 4 mM in RPMI-B27 minus insulin
in all cases. Over a 48-hr period, we observed dynamic
changes in the gene expression pattern (Figure S2A) similar
to those previously observed for the hESC line H1. On
completion of phase I (48 hr), we observed elevated
expression of DE markers such as FOXA2, GSC, SOX17,
HHEX, and CER1. These changes in gene expression were
accompanied by morphological changes consistent with
the hESC line H1 differentiation above (Figure S2B). At
the 48-hr time point (phase I endpoint), we observed co-
expression of FOXA2 and SOX17 at the protein level using
immunofluorescence (Figure S2C). All lines gave similar
efficiencies with respect to FOXA2- and SOX17-positive(E) Efficiency of phase III differentiation, determined by counting albu
positive cells. Efficiencies are presented as the percentage of positiv
(F) RT-PCR of CYP7A1 gene expression of H1-derived smHLCs. Lane 1
expression; lanes 2–4 (lower panel), ACTB loading control.
See also Figure S6.
Stemcells: 81%–84% for FOXA2 and 79%–82% for SOX17 (Fig-
ure S2D). To ensure that hiPSCs were following a develop-
mentally relevant route, we assessed the timing of key
events in DE specification. Figure S3 shows induction of
the PS markers T, GSC, and NODAL in the first 24 hr.
This is followed by specification to definitive endoderm
indicated by robust induction of SOX17, GSC, FOXA2,
and MIXL1 (Figure S3) and no significant upregulation of
SOX7 (Figure S2A).
On confirmation of DE specification, we next sought to
specify a hepatic fate. We utilized the same phase II con-
ditions (DMSO) as described above. After the 5 days of
treatment, we observed a rapid change in morphology,
accompanied with proliferation. For all lines tested, we
observed typical hepatic progenitor morphology as as-
sessed by phase contrast microscopy (Figure S4A). We
observed efficiencies of between 86% and 89% based on
AFP/HNF4A co-expression, as assessed by immunofluores-
cence (Figures S4B and S4C). Gene expression was
analyzed after the end of hepatic specification by qRT-
PCR, at which point we observed equivalent expression
profiles as hESC H1 (Figure S4D). In addition, as with
the hESC line H1, we performed a time course over
5 days and observed a very similar developmental marker
profile (Figure S5). The validated hepatic progenitor cells
from the different hPSCs were then subjected to phase
III differentiation (Figures 1C and S1C). On completion
of the differentiation, all lines efficiently generated
smHLCs as assessed by morphology (Figure S6A). All lines
demonstrated extensive expression of ALB/ HNF4A and
alpha-1-antitrypsin by immunofluorescence (Figures S6B
and S6C). Both hESC line 207 and hiPSC-derived smHLCs
secreted albumin, alpha-1-antitrypsin, and fibronectin as
assessed by ELISA. All three proteins were detected in
the medium at levels similar to those observed for H1 (Fig-
ures S7A). We demonstrated that the hiPSC-derived
smHLCs were from a DE origin via the presence of
CYP7A1 (Figure S7B). We observed comparable efficiency
of smHLC production to hESC H1 (between 72% and
79% for ALB/HNF4A and between 88% and 92% for
A1AT; Figure S7C). Finally we assessed the expression
levels of the following hepatocyte markers: A1AT
(SERPINA1), AFP, ALB, APOA2, ASGR1, CYP3A4, HNF4A,
TDO2, and TTR by qRT-PCR, and profiles very similar to
H1-derived smHLCs were observed (Figure S7C). Thus,
we demonstrated that our protocol was applicable to
other hESC and hiPSC lines.min and HNF4A double-positive cells, A1AT-positive cells, and AFP-
e cells plus or minus the SD of all fields counted.
, hESC H1 control; lanes 2–4 (top panel), H1 day 17 HLCs CYP7A1
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Figure 7. Characterization of Phase III Differentiation to Hepatocyte-like Cells: qRT-PCR and Functional Analysis
(A) Expression of A1AT (SERPINA1), AFP, ALB, APOA2, ASGR1, CYP3A4, HNF4A, TDO2, and TTR at endpoint of small-molecule (blue) and
growth-factor (red) protocols, as well as primary adult and fetal hepatocyte controls, assessed by TaqMan. Normalized to ACTB and small-
molecule- or growth-factor-derived definitive endoderm, respectively. Data are presented as the mean of three independent experiments;
error bars represent SD. Because only one primary fetal control was run, no error bars are present.
(B) Cytochrome P450 1A2 and 3A4 activity and induction were assessed in both smHLCs (SM) and growth-factor-derived HLCs (GF). The
black columns represent hESC H1 pluripotent control, the blue columns represent basal activity, and the orange columns represent activity
after induction with either omeprazole (1A2) or rifampicin (3A4). Data are presented as the mean of six independent experiments; error
bars represent SD (n = 6 biological replicates). GF CYP1A2 *p < 0.05, **p < 0.002; SM CYP1A2 *p < 0.02, **p < 0.01; ***p < 0.001. GF
CYP3A4 *p < 0.001, **p < 0.005; SM CYP3A4 *p < 0.004, **p < 0.0002; ***p < 2 3 105.
(C) Serum protein secretion at endpoint of both growth-factor- (red) and small-molecule-based (blue) protocols. Data are presented as the
mean of three independent experiments; error bars represent SD. *p < 0.09, **p < 0.004, compared to control.
(D) Glycogen storage in growth-factor- and small-molecule-differentiated cells as indicated by PAS staining. Treatment is indicated top
left of each panel. Scale bars, 100 mm.
(E) H1 smHLCs treated for 1 hr with 1 mg/ml indocyanine green demonstrate uptake as assessed by phase microscopy. Scale bars, 100 mm.
See also Figure S7.DISCUSSION
We have developed a protocol for the efficient differentia-
tion of functional HLCs from hPSCs that does not require
the addition of recombinant growth factors and is appli-948 Stem Cell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authocable to both hESCs and hiPSCs. During the development
of the protocol, it came as a surprise to discover that plurip-
otent cells can be differentiated to DE with a short
pulse (24 hr) of CHIR99021, BIO, or Wnt3a without the
inclusion of activin A. The rationale to examine GSK-3rs
inhibition as a route to producing DE has a basis in the
observations of Lickert and colleagues (Engert et al.,
2013), who demonstrated that Wnt signaling regulates
SOX17 expression. A number of other publications also
describe the priming activity of GSK-3 inhibitors such as
CHIR99021 (Hannan et al., 2013; Kunisada et al., 2012;
Tahamtani et al., 2013; Tan et al., 2013). In this study, we
clearly demonstrate that GSK-3 inhibition alone is suffi-
cient to produce DE, a finding that in itself represents an
opportunity for major saving in hepatocyte-production
costs. Importantly, this first stage provided productive
DE, which expressed a battery of DE markers including
SOX17 and FOXA2, and passed through the equivalent
developmental points as growth factor DE (Figure 2A).
The use of DMSO to drive DE toward a hepatic fate is well
established in the field (Hay et al., 2008; Soto-Gutie´rrez
et al., 2007; Sullivan et al., 2010), and we show here
that it is equally successful when employed following
CHIR99021 treatment as with activin A and Wnt3a. We
observed a rapid change in morphology, coupled with the
appearance of the hepatic progenitor markers HNF4A and
AFP, both at the transcriptional and protein levels. The final
phase of this protocol was to take hepatic progenitors and
provide the environment for hepatocyte maturation in
order to generate HLCs. We chose to utilize a combination
of two small molecules of the glucocorticoid family, DEX
and hydrocortisone-21-hemisuccinate (HC), and assessed
the literature for potential mimetics of commonly used
growth factors. We identified a potent HGF mimetic called
N-hexanoic-Tyr, Ile-(6) aminohexanoic amide, or dihexa,
originally developed as an anti-dementia drug (McCoy
et al., 2013). This molecule was identified in a screen that
assessed the capacity to potentiate the biological activity
of HGF. We therefore employed the small molecules DEX,
HC and dihexa in phase III of the protocol. Initially, phase
III was optimized using the commercially available base
mediumHepatoZYME that has been shown to provide sup-
portive conditions for hepatocyte maturation (Szkolnicka
et al., 2014). We demonstrated the dependency of dihexa
in this system (data not shown), but it transpired that
HepatoZYME is not growth factor free and contains the
morphogen EGF (Garcia et al., 2001). We then translated
our findings to the routinely used hepatocyte maturation
medium L-15, which others have used supplemented
with a combination of growth factors and small molecules
(Hay et al., 2008; Sullivan et al., 2010). We supplemented
L-15 with the aforementioned small molecules and effi-
ciently generated HLCs from both hESCs and hiPSCs,
which displayed typical hepatic morphology and ex-
pressed a number of hepatic markers at the transcriptional
and protein levels. More importantly, the smHLCs ex-
hibited key functional attributes including serum protein
production and cytochrome P450 metabolism. It shouldStembe stated that we used the P450-Glo assay system
(Promega) to initially assess function with respect to CYP
activity as in line with many other publications. But,
in order to gain a thorough insight into the metabolic
potential of these cells, we will need to assess them
using the more robust and accepted methods including
mass spectrometry and high-performance liquid chroma-
tography. It should be noted that the above method
is not fully defined at this point, as the present L-15
formulation contains 8.3% serum. We are currently inves-
tigating avenues to generate a completely defined system
for the production of hepatocytes, but the method
described here represents a significant step toward this
goal and is applicable to both hESC and hiPSC lines. Impor-
tantly, it provides a means to cut the costs associated
with hepatocyte production. A combination of this small-
molecule approach with the steadily advancing field of
cell-culture automation may eventually allow for the pro-
duction of high-quality hepatocytes from stem cells at large
scale for industrial and clinical translation. In the mean-
time, this approach in our hands produces cells of equiva-
lent phenotype and function to current approaches and
addresses some of the cost, quality, and supply-chain con-
cerns associated with reliance on recombinant growth
factors.
In conclusion, we demonstrate here the efficient genera-
tion of both hESC- and hiPSC-derived HLCs through the
use of smallmolecules, removing the longstanding reliance
on recombinant growth factors. This may go on to provide
the foundations for scalable hepatocyte production for use
in disease modeling, cell therapy, drug discovery, and basic
research in terms of improving maturity and function
in vitro.EXPERIMENTAL PROCEDURES
Cell Culture
H1 hESCs (WiCell) and 207 hESCs (Stro¨m et al., 2010) and Detroit
551 (ATCC CCL-110) hiPSCs were maintained at 37C/5% CO2
in feeder-free conditions using growth-factor-reduced Matrigel
(Sigma-Aldrich) and E8 Medium (Life Technologies), with routine
passaging performed at a 1:3 ratio using 0.5 mM EDTA (Life
Technologies). All Matrigel plates were coated with a 1:48 dilution
in Advanced DMEM-F12 (Life Technologies) and incubated at
37C/5% CO2 for 1 hr prior to use.
Hepatocyte Differentiation
Cells were seeded onto Matrigel-coated 12-well plates in E8 me-
dium at a 1:3–1:4 split ratio and allowed to adhere for 24 hr at
37C/5% CO2. It should be noted that the optimal cell density
for each line needs to be established. The cells were washed with
PBS before being treated with differentiation media. The differen-
tiation protocol utilizes a base media similar to a well-established
differentiation protocol (Hay et al., 2008), with replacement ofCell Reports j Vol. 4 j 939–952 j May 12, 2015 j ª2015 The Authors 949
all growth factors with small molecules and minor adjustments in
timing. The protocol incorporates several stages (Figure 1) utilizing
different small molecules.
Phase I of differentiation consists of a 24-hr treatment with
RPMI-B27 ± insulin (RPMI 1640 GlutaMAX + B27 supplement,
both from Life Technologies) plus 3–4 mM CHIR99021 (Stem-
gent), followed by a 24-hr treatment with RPMI-B27 alone.
Phase II consists of 5 days of treatment with knockout DMEM
containing 20% knockout serum replacement, 2 mM GlutaMAX,
100 mM 2-mercaptoethanol, 13 MEM non-essential amino acids
(Life Technologies), and 1% DMSO (Sigma-Aldrich). Phase III
consists of 10 days of treatment with Leibovitz L-15 media
containing 8.3% tryptose phosphate broth, 10 mM hydrocorti-
sone 21-hemisuccinate, 50 mg/ml sodium-L-ascorbate, 100 nM
dexamethasone (all from Sigma-Aldrich), 0.58% insulin-trans-
ferrin-selenium (ITS), 2 mM GlutaMAX (all from Life Technolo-
gies), 8.3% fetal bovine serum (Lonza), and 100 nM dihexa
(a kind gift from Prof. Joseph Harding, Washington State
University). During phases II and III, cells are fed every 48 hr.
Cells were photographed during differentiation using a Zeiss
phase contrast microscope and ZEN software. The scale bars
represent 100 mm.
Control H1 hESCs (growth factor) were differentiated using acti-
vin A,Wnt3a, DMSO, OSM, and HGF (Peprotech) as described pre-
viously (Hay et al., 2008; Sullivan et al., 2010). All small molecules
were made up in DMSO; vehicle control differentiations were per-
formed using equivalent concentrations.
Small Molecules
For a complete list of small molecules, sources, and purity, please
see Table S4.
Detailed methods are described in the Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and four tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
2015.04.001.
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